Kowa and Daiichi Sankyo to end joint marketing partnership in Japan

7 April 2013

Privately-held Japanese drugmaker Kowa and pharma major Daiichi Sankyo (TYO: 4568) say they will be ending their joint marketing partnership for sales of Livalo (pitavastatin calcium) tablets, a cholesterol-lowering agent, and Olmetec (olmesartan medoxomil) tablets, an antihypertensive agent, as of June 30, 2013.

Just a few days earlier, Daiichi Sankyo returned worldwide rights for the development and commercialization of compounds covered under its AKT collaboration with loss-making US drug developer ArQule (Nasdaq: ARQL), including the lead compound emerging from this collaboration, ARQ 092 (The Pharma Letter April 3).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK